Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation
Key facts
- Who runs it
- Moscow Multidisciplinary Clinical Center "Kommunarka"
- Where
- Russia7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 76 people, planned
- Started
- 25 Jun 2026
- Expected to end
- 25 Dec 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Efferon LPS
- Toramyxin PMX 20R
- Jafron HA 330
- CytoSorb
- Record updated
- 2 July 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Septic shock according to SEPSIS-3 criteria
- Age: 18-80 years
- SOFA ≥9 points
- Diagnosis of septic shock established <12 hours ago
- Invasive hemodynamic monitoring
- Norepinephrine dose >0.2 mcg/kg/min
Who cannot take part
- End-stage heart failure (NYHA stage IV)
- Ongoing bleeding
- HIV infection
- Patients with oncohematological diseases
- Patients with a recognized palliative status or the definition of "metastatic cancer"
- Absolute neutrophil count less than 500 cells/μL
- Pregnancy
- Pulmonary embolism with obstructive shock
- Atonic coma
- More than 30 points on the MELD scale, class C on the Child-Pugh scale
- Burns over 10% of the body surface area
- RRT using membranes with a high cutoff point and increased adsorption capacity within 72 hours from the initiation of the first hemoadsorption procedure
- Use of plasma exchange within 72 hours from the initiation of the first hemoadsorption procedure
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Septic shock
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial.
Read full original descriptionShow less
The goal of this clinical trial is the estimation of the efficacy and safety of hemoadsorption procedures (LPS (Lipopolysaccharide) and inflammatory mediators adsorption) in participants with septic shock.
The main questions it aims to answer are:
Does hemoadsorption decrease the severity of MODS (multiple organ disfunction syndrome)?
The study will include participants aged 18 to 80 years with a verified diagnosis of septic shock according to SEPSIS 3 criteria, diagnosed within 12 hours, and a SOFA (sequential organ failure assessment) score of 9 or more.
In addition to Standard of Care (SOC), blood purification, including hemoadsorption, will be used. The minimum waiting time after diagnosis of septic shock and initiation of basic therapy before inclusion of the patient in the study therapy is 4 hours.
The choice of procedure will be based on the EAA (Endotoxin Activity Assay) result:
* for an EAA level of 0.6-0.9, selective lipopolysaccharide (LPS) adsorption with duration from 2 to 10 hours; * for an EAA level less than 0.6, inflammatory mediator adsorption with duration from 6 to 12 hours.
The choice of a specific adsorbers within the LPS and inflammatory mediator adsorption group will be based on randomization.
The use of LPS adsorption is planned based on randomization: Toramyxin R-20 or Efferon LPS. The use of inflammatory mediator adsorption is planned based on randomization: Jafron (HA 330) or CytoSorb.
The 4 groups in the trial
- Inflammatory mediatiors adsorption with CytoSorbTreatment being tested
Inflammatory mediatiors adsorption with EAA \<0,6 with CytoSorb
Treatment: CytoSorb
- Inflammatory mediatiors adsorption with Jafron HA 330Existing treatment, for comparison
Inflammatory mediatiors adsorption with EAA \<0,6 with Jafron HA 330
Treatment: Jafron HA 330
- Endotoxin haemoadsorption with Toramyxin PMX 20RTreatment being tested
Endotoxin haemoadsorption with EAA \[0.6-0.9\] with Toramyxin PMX 20R
Treatment: Toramyxin PMX 20R
- Endotoxin haemoadsorption with Efferon LPSExisting treatment, for comparison
Endotoxin haemoadsorption with EAA \[0.6-0.9\] with Efferon LPS
Treatment: Efferon LPS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial
- Criteria questions
- Built from NCT07661303, who can take part
- Record updated
- 2 July 2026